MedDataX Logo

Epidemiological Study to Describe Non-small-cell Lung Carcinoma (NSCLC) Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA

NCT ID: NCT01330862

Last Updated: 2012-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

54 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is to provide accurate, reliable information on NSCLC clinical management across MENA (Middle East North Africa) countries in order to detect unmet medical needs of this disease, it is a purely observational study; therefore patients are not assigned to a particular therapeutic strategy beforehand by a protocol. Treatment will be according to current clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NSCLC Patient Characteristics

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

patient outcomes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between April 1st 2011 and March 31 2012, for PRO sub-sample: ability to read and write since they will be asked to participate in the PRO part of the study. Selection will not be based on the disease stage of each patient, in order to avoid a selection bias
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Abdul Rahman Jazieh

Role: STUDY_CHAIR

King Fahad National Guard Hospital

Dr. Ahmed Abdulwarith

Role: PRINCIPAL_INVESTIGATOR

King Fahad Specialist Hospital

Dr. Rasha Moastafa

Role: PRINCIPAL_INVESTIGATOR

King Fahad Medical City

Dr. Sherif Wafa

Role: PRINCIPAL_INVESTIGATOR

Prince Faisal Bin Bander oncology centre

Dr. Maged Mansour

Role: PRINCIPAL_INVESTIGATOR

Dr. Erfan & Bagedo Hospital

Dr. Mohamed Rahhal

Role: PRINCIPAL_INVESTIGATOR

King Fahad Specialist Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Qassim, Central, Saudi Arabia

Site Status

Research Site

Riyadh, Central, Saudi Arabia

Site Status

Research Site

Dammam, Eastern Province, Saudi Arabia

Site Status

Research Site

Jeddah, Western, Saudi Arabia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-MENA-SA-IRS-2010/01

Identifier Type: -

Identifier Source: org_study_id